JAK2V617F influences epigenomic changes in myeloproliferative neoplasms

Chih Cheng Chen, Chia Chen Chiu, Kuan Der Lee, Chia Chen Hsu, Hong Chi Chen, Tim H.M. Huang, Shu Huei Hsiao, Yu Wei Leu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Negative valine (V) to phenylalanine (F) switch at the Janus kinase (JAK2) 617 codon (V617F) is the dominant driver mutation in patients with myeloproliferative neoplasms (MPNs). JAK2V617F was proved to be sufficient for cell transformation; however, independent mutations might influence the following epigenomic modifications. To assess the JAK2V617F-induced downstream epigenomic changes without interferences, we profiled the epigenomic changes in ectopically expressed JAK2V617F in Ba/F3 cells. Antibodies against phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and enhancer of zeste homolog 2 (EZH2) were used for chromatin-immunoprecipitation sequencing (ChIP-seq) to detect the downstream epigenomic targets in the JAK2–STAT3 signaling pathway. To confirm the JAK2V617F-induced epigenetic changes in vivo, DNA methylation changes in the target loci in patients with MPNs were detected through methylation-specific polymerase chain reaction and were clustered against the changes within controls. We found that ectopically expressed JAK2V617F in Ba/F3 cells reduced the binding specificity; it was associated with cis-regulatory elements and recognized DNA motifs in both pSTAT3-downstream and EZH2-associated targets. Overlapping target loci between the control and JAK2V617F were <3% and 0.4%, respectively, as identified through pSTAT3 and EZH2 ChIP-seq. Furthermore, the methylation changes in the direct target loci (FOXH1, HOXC9, and SRF) were clustered independently from the control locus (L1TD1) and other mutation genes (HMGA2 and Lin28A) in the analyzed MPN samples. Therefore, JAK2V617F influences target binding in both pSTAT3 and EZH2. Without mutations in epigenetic regulators, JAK2V617F can induce downstream epigenomic modifications. Thus, epigenetic changes in JAK2 downstream targets might be trackable in vivo.

Original languageEnglish
Pages (from-to)470-476
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume494
Issue number3-4
DOIs
Publication statusPublished - Dec 16 2017

Fingerprint

STAT3 Transcription Factor
Epigenomics
Methylation
Chromatin
Neoplasms
Janus Kinases
Mutation
Internal-External Control
Chromatin Immunoprecipitation
Polymerase chain reaction
Valine
Phenylalanine
Genes
Switches
Nucleotide Motifs
Antibodies
DNA
DNA Methylation
Codon
Polymerase Chain Reaction

Keywords

  • DNA methylation
  • Epigenetics
  • Myeloproliferative neoplasms
  • V617F mutation

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

JAK2V617F influences epigenomic changes in myeloproliferative neoplasms. / Chen, Chih Cheng; Chiu, Chia Chen; Lee, Kuan Der; Hsu, Chia Chen; Chen, Hong Chi; Huang, Tim H.M.; Hsiao, Shu Huei; Leu, Yu Wei.

In: Biochemical and Biophysical Research Communications, Vol. 494, No. 3-4, 16.12.2017, p. 470-476.

Research output: Contribution to journalArticle

Chen, Chih Cheng ; Chiu, Chia Chen ; Lee, Kuan Der ; Hsu, Chia Chen ; Chen, Hong Chi ; Huang, Tim H.M. ; Hsiao, Shu Huei ; Leu, Yu Wei. / JAK2V617F influences epigenomic changes in myeloproliferative neoplasms. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 494, No. 3-4. pp. 470-476.
@article{f870b6a9934740ab94506dd36e154367,
title = "JAK2V617F influences epigenomic changes in myeloproliferative neoplasms",
abstract = "Negative valine (V) to phenylalanine (F) switch at the Janus kinase (JAK2) 617 codon (V617F) is the dominant driver mutation in patients with myeloproliferative neoplasms (MPNs). JAK2V617F was proved to be sufficient for cell transformation; however, independent mutations might influence the following epigenomic modifications. To assess the JAK2V617F-induced downstream epigenomic changes without interferences, we profiled the epigenomic changes in ectopically expressed JAK2V617F in Ba/F3 cells. Antibodies against phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and enhancer of zeste homolog 2 (EZH2) were used for chromatin-immunoprecipitation sequencing (ChIP-seq) to detect the downstream epigenomic targets in the JAK2–STAT3 signaling pathway. To confirm the JAK2V617F-induced epigenetic changes in vivo, DNA methylation changes in the target loci in patients with MPNs were detected through methylation-specific polymerase chain reaction and were clustered against the changes within controls. We found that ectopically expressed JAK2V617F in Ba/F3 cells reduced the binding specificity; it was associated with cis-regulatory elements and recognized DNA motifs in both pSTAT3-downstream and EZH2-associated targets. Overlapping target loci between the control and JAK2V617F were <3{\%} and 0.4{\%}, respectively, as identified through pSTAT3 and EZH2 ChIP-seq. Furthermore, the methylation changes in the direct target loci (FOXH1, HOXC9, and SRF) were clustered independently from the control locus (L1TD1) and other mutation genes (HMGA2 and Lin28A) in the analyzed MPN samples. Therefore, JAK2V617F influences target binding in both pSTAT3 and EZH2. Without mutations in epigenetic regulators, JAK2V617F can induce downstream epigenomic modifications. Thus, epigenetic changes in JAK2 downstream targets might be trackable in vivo.",
keywords = "DNA methylation, Epigenetics, Myeloproliferative neoplasms, V617F mutation",
author = "Chen, {Chih Cheng} and Chiu, {Chia Chen} and Lee, {Kuan Der} and Hsu, {Chia Chen} and Chen, {Hong Chi} and Huang, {Tim H.M.} and Hsiao, {Shu Huei} and Leu, {Yu Wei}",
year = "2017",
month = "12",
day = "16",
doi = "10.1016/j.bbrc.2017.10.108",
language = "English",
volume = "494",
pages = "470--476",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Elsevier B.V.",
number = "3-4",

}

TY - JOUR

T1 - JAK2V617F influences epigenomic changes in myeloproliferative neoplasms

AU - Chen, Chih Cheng

AU - Chiu, Chia Chen

AU - Lee, Kuan Der

AU - Hsu, Chia Chen

AU - Chen, Hong Chi

AU - Huang, Tim H.M.

AU - Hsiao, Shu Huei

AU - Leu, Yu Wei

PY - 2017/12/16

Y1 - 2017/12/16

N2 - Negative valine (V) to phenylalanine (F) switch at the Janus kinase (JAK2) 617 codon (V617F) is the dominant driver mutation in patients with myeloproliferative neoplasms (MPNs). JAK2V617F was proved to be sufficient for cell transformation; however, independent mutations might influence the following epigenomic modifications. To assess the JAK2V617F-induced downstream epigenomic changes without interferences, we profiled the epigenomic changes in ectopically expressed JAK2V617F in Ba/F3 cells. Antibodies against phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and enhancer of zeste homolog 2 (EZH2) were used for chromatin-immunoprecipitation sequencing (ChIP-seq) to detect the downstream epigenomic targets in the JAK2–STAT3 signaling pathway. To confirm the JAK2V617F-induced epigenetic changes in vivo, DNA methylation changes in the target loci in patients with MPNs were detected through methylation-specific polymerase chain reaction and were clustered against the changes within controls. We found that ectopically expressed JAK2V617F in Ba/F3 cells reduced the binding specificity; it was associated with cis-regulatory elements and recognized DNA motifs in both pSTAT3-downstream and EZH2-associated targets. Overlapping target loci between the control and JAK2V617F were <3% and 0.4%, respectively, as identified through pSTAT3 and EZH2 ChIP-seq. Furthermore, the methylation changes in the direct target loci (FOXH1, HOXC9, and SRF) were clustered independently from the control locus (L1TD1) and other mutation genes (HMGA2 and Lin28A) in the analyzed MPN samples. Therefore, JAK2V617F influences target binding in both pSTAT3 and EZH2. Without mutations in epigenetic regulators, JAK2V617F can induce downstream epigenomic modifications. Thus, epigenetic changes in JAK2 downstream targets might be trackable in vivo.

AB - Negative valine (V) to phenylalanine (F) switch at the Janus kinase (JAK2) 617 codon (V617F) is the dominant driver mutation in patients with myeloproliferative neoplasms (MPNs). JAK2V617F was proved to be sufficient for cell transformation; however, independent mutations might influence the following epigenomic modifications. To assess the JAK2V617F-induced downstream epigenomic changes without interferences, we profiled the epigenomic changes in ectopically expressed JAK2V617F in Ba/F3 cells. Antibodies against phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and enhancer of zeste homolog 2 (EZH2) were used for chromatin-immunoprecipitation sequencing (ChIP-seq) to detect the downstream epigenomic targets in the JAK2–STAT3 signaling pathway. To confirm the JAK2V617F-induced epigenetic changes in vivo, DNA methylation changes in the target loci in patients with MPNs were detected through methylation-specific polymerase chain reaction and were clustered against the changes within controls. We found that ectopically expressed JAK2V617F in Ba/F3 cells reduced the binding specificity; it was associated with cis-regulatory elements and recognized DNA motifs in both pSTAT3-downstream and EZH2-associated targets. Overlapping target loci between the control and JAK2V617F were <3% and 0.4%, respectively, as identified through pSTAT3 and EZH2 ChIP-seq. Furthermore, the methylation changes in the direct target loci (FOXH1, HOXC9, and SRF) were clustered independently from the control locus (L1TD1) and other mutation genes (HMGA2 and Lin28A) in the analyzed MPN samples. Therefore, JAK2V617F influences target binding in both pSTAT3 and EZH2. Without mutations in epigenetic regulators, JAK2V617F can induce downstream epigenomic modifications. Thus, epigenetic changes in JAK2 downstream targets might be trackable in vivo.

KW - DNA methylation

KW - Epigenetics

KW - Myeloproliferative neoplasms

KW - V617F mutation

UR - http://www.scopus.com/inward/record.url?scp=85032643396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032643396&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.10.108

DO - 10.1016/j.bbrc.2017.10.108

M3 - Article

AN - SCOPUS:85032643396

VL - 494

SP - 470

EP - 476

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3-4

ER -